Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 503 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 503 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, March 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $58.69, for a total value of $293,450.00.
• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total value of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Stock Down 3.0 %

HALO stock traded down $1.94 during mid-day trading on Tuesday, hitting $61.87. The stock had a trading volume of 1,407,707 shares, compared to its average volume of 1,378,411. The company has a fifty day moving average of $59.34 and a 200 day moving average of $54.84. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. Vanguard Group Inc. lifted its stake in shares of Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after buying an additional 386,618 shares during the period. Snyder Capital Management L P lifted its position in Halozyme Therapeutics by 2.6% in the fourth quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock worth $199,294,000 after purchasing an additional 105,086 shares during the period. Geode Capital Management LLC boosted its stake in Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after buying an additional 30,901 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock valued at $92,446,000 after buying an additional 47,795 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company’s stock valued at $87,386,000 after buying an additional 145,617 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HALO shares. Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Benchmark reissued a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.